oNKo-001

PROGRESS – Approaching Lead Candidate

Eliminating solid tumors without toxicity

An engineered Fc-fusion protein, oNKo-001 aims to widen the therapeutic window of the IL-12 cytokine by reducing toxicity and enhancing its pharmacokinetic profile, all while maintaining its impressive anti-tumor function.

oNKo-002

PROGRESS – Lead Candidate

Novel immunotherapy biologic

ONKo-002 is a biologic that enhances the anti-cancer activity of Natural Killer and T cells by acting on an undisclosed target that was illuminated by our CRISPR screening platform.

oNKo-037

PROGRESS – Hit Generation

Novel targets to super-charge cytotoxic lymphocyte function

oNKo-037 is our most advanced small molecule program and it represents a novel immunotherapy target. Genetic manipulation of oNKo-037 enhances fitness of natural killer and T cells by increasing sensitivity to endogenous IL-15 cytokines.

oNKo-038 & oNKo-046

PROGRESS – Target Validation

Undisclosed CAR-NK cell edits

Our primary human NK cell CRISPR screens identified a number of novel genetic edits that enhance fitness and anti-tumour function of CAR-NK cells. oNKo-038 and oNKo-046 are intracellular checkpoints in orthogonal cytokine pathways that when paired together lead to impressive CAR-NK cell function under repetitive antigen stimulation and immunosuppressive conditions.

oNKo-044

PROGRESS – Approaching Lead Series

IL-12v ABD Fc

A fourth-generation engineered IL-12 cytokine-antibody fusion protein, oNKo-044 is targeted to enhance anti-tumour immune cells while further minimising off-target toxicity.